Pierard, Gérald ; Université de Liège > Département des sciences cliniques > Département des sciences cliniques
PAQUET, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Dermatologie
Jennes, Serge
Franchimont, Claudine ; Université de Liège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Lyell, A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68: 355-361.
Lyell, A. Requiem for toxic epidermal necrolysis. Br J Dermatol 1990; 122: 837-838.
Forman, R; Koren, G; Shear, NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf 2002; 25: 965-972.
Prendiville, J. Stevens-Johnson syndrome and toxic epidermal necrolysis. Adv Dermatol 2002; 18: 151-173.
Wolf, R; Wolf, D; Davidovici, B. In the pursuit of classifying severe cutaneous adverse reactions. Clin Dermatol 2007; 25: 348-349.
Paquet, P; Piérard, GE. New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited. Drug Saf 2010; 33: 189-212.
Ducic, I; Shalom, A; Rising, W, et al. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg 2002; 110: 768-773.
Schneck, J; Fagot, JP; Sekula, P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis:A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40.
Piérard, GE; Paquet, P. Facing up to toxic epidermal necrolysis. Expert Opin Pharmacother 2010; 11: 2443-2446.
Gravante, G; Esposito, G; Delogu, D, et al. More than two different bacterial species isolated from blood of toxic epidermal necrolysis patients significantly increase mortality. Burns 2006; 32: 793-794.
Jin, H; Qiao, J; Wang, B, et al. Toxic epidermal necrolysis complicated by Mucor infection. Int J Dermatol 2008; 47: 383-386.
de Prost, N; Ingen-Housz-Oro, S; Duong, T, et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore) 2010; 89: 28-36.
Fritsch, PO; Sidoroff, A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000; 1: 349-360.
Schulz, JT; Sheridan, RL; Ryan, CM, et al. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000; 21: 199-204.
Noël, JC; Buxant, F; Fayt, I, et al. Vulval adenosis associated with toxic epidermal necrolysis. Br J Dermatol 2005; 153: 457-458.
Abood, GJ; Nickoloff, BJ; Gamelli, RL. Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? J Burn Care Res 2008; 29: 269-276.
Gerull, R; Nelle, M; Schaible, T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med 2011; 39: 1521-1532.
Castelain, F; Humbert, P. Toxic epidermal necrolysis. Curr Drug Saf 2012; 7: 332-338.
Harr, T; French, LE. Stevens-Johnson syndrome and toxic epidermal necrolysis. Chem Immunol Allergy 2012; 97: 149-166.
Saka, B; Barro-Traore, F; Atadokpede, FA, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. Int J Dermatol 2013; 52: 575-579.
Schwartz, RA; McDonough, PH; Lee, BW. Toxic epidermal necrolysis:Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol 2013; 69: 173 e171-113; quiz 185-176.
Schwartz, RA; McDonough, PH; Lee, BW. Toxic epidermal necrolysis:Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol 2013; 69: 187 e181-116; quiz 203-184.
Piérard-Franchimont, C; Quatresooz, P; Reginster, MA, et al. Finding the drug in cutaneous drug eruptions. Rev Med Liege 2011; 66: 474-477.
Hermanns-Lê, T; Piérard-Franchimont, C; Piérard, GE. The spectrum of drug eruptions. Rev Med Liege 2013; 68: 44-50.
Endorf, FW; Cancio, LC; Gibran, NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res 2008; 29: 706-712.
Mulvey, JM; Padowitz, A; Lindley-Jones, M, et al. Mycoplasma pneumoniae associated with Stevens Johnson syndrome. Anaesth Intensive Care 2007; 35: 414-417.
Neuman, MG; McKinney, KK; Nanau, RM, et al. Drug-induced severe adverse reaction enhanced by human herpes virus-6 reactivation. Transl Res 2013; 161: 430-440.
Downey, A; Jackson, C; Harun, N, et al. Toxic epidermal necrolysis:review of pathogenesis and management. J Am Acad Dermatol 2012; 66: 995-1003.
Reilly, TP; Lash, LH; Doll, MA, et al. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000; 114: 1164-1173.
Baron, JM; Merk, HF. Drug metabolism in the skin. Curr Opin Allergy Clin Immunol 2001; 1: 287-291.
Vyas, PM; Roychowdhury, S; Koukouritaki, SB, et al. Enzymemediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: II. Expression and role of flavin-containing monooxygenases and peroxidases. J Pharmacol Exp Ther 2006; 319: 497-505.
Dietrich, A; Kawakubo, Y; Rzany, B, et al. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol 1995; 4: 313-316.
Paquet, P; Jacob, E; Pirson, J, et al. Drug-induced toxic epidermal necrolysis and pancytopenia: a puzzling association. Int J Mol Med 2005; 16: 29-33.
Paquet, P; Nikkels, A; Arrese, JE, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol 1994; 130: 605-608.
Paquet, P; Piérard, GE. Keratinocyte injury in drug-induced toxic epidermal necrolysis: Simultaneous but distinct topographic expression of CD95R and calprotectin. Int J Mol Med 2002; 10: 145-147.
Piérard-Franchimont, C; Lesuisse, M; Humbert, P, et al. Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy. Curr Drug Saf 2012; 7: 357-360.
Halevi, A; Ben-Amitai, D; Garty, BZ. Toxic epidermal necrolysis associated with acetaminophen ingestion. Ann Pharmacother 2000; 34: 32-34.
Chave, TA; Mortimer, NJ; Sladden, MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153: 241-253.
Tohyama, M; Hashimoto, K. Immunological mechanisms of epidermal damage in toxic epidermal necrolysis. Curr Opin Allergy Clin Immunol 2012; 12: 376-382.
Khalili, B; Bahna, SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 2006; 97: 272-280; quiz 281-273, 320.
Posadas, SJ; Padial, A; Torres, MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002; 109: 155-161.
Posadas, SJ; Torres, MJ; Mayorga, C, et al. Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs. Blood Cells Mol Dis 2002; 29: 179-189.
Paquet, P; Piérard, GE. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol 1997; 19: 127-132.
Redondo, P; Vicente, J; Espana, A, et al. Photo-induced toxic epidermal necrolysis caused by clobazam. Br J Dermatol 1996; 135: 999-1002.
Paquet, P; Piérard, GE. Soluble fractions of tumor necrosis factor-alpha, interleukin-6 and of their receptors in toxic epidermal necrolysis: a comparison with second-degree burns. Int J Mol Med 1998; 1: 459-462.
Correia, O; Delgado, L; Roujeau, JC, et al. Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch Dermatol 2002; 138: 29-32.
Paquet, P; Jacob, E; Piérard, GE. Cystic lesion of the parotid following drug-induced toxic epidermal necrolysis (Lyell's syndrome). J Oral Pathol Med 2005; 34: 380-382.
Sibaud, V; Fricain, JC; Leaute-Labreze, C, et al. Persistant mucosal ulcerations: a rare complication of toxic epidermal necrolysis. Ann Dermatol Venereol 2005; 132: 682-685.
Sedghizadeh, PP; Kumar, SK; Gorur, A, et al. Toxic epidermal necrolysis with a rare long-term oral complication requiring surgical intervention. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105: e29-33.
Chang, YS; Huang, FC; Tseng, SH, et al. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007; 26: 123-129.
Yip, LW; Thong, BY; Lim, J, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy 2007; 62: 527-531.
Sotozono, C; Ueta, M; Koizumi, N, et al. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology 2009; 116: 685-690.
Hsu, M; Jayaram, A; Verner, R, et al. Indications and outcomes of amniotic membrane transplantation in the management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Cornea 2012; 31: 1394-1402.
Di Pascuale, MA; Espana, EM; Liu, DT, et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology 2005; 112: 904-912.
De Rojas, MV; Dart, JK; Saw, VP. The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol 2007; 91: 1048-1053.
Schulze Schwering, M; Kayange, P; van Oosterhout, JJ, et al. Severe eye complications from Stevens-Johnson syndrome in a human immunodeficiency virus-infected patient in Malawi. Am J Trop Med Hyg 2013; 89: 162-164.
Lopez-Garcia, JS; Rivas Jara, L; Garcia-Lozano, CI, et al. Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis. Ophthalmology 2011; 118: 265-271.
Morales, ME; Purdue, GF; Verity, SM, et al. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN. Am J Ophthalmol 2010; 150: 505-510 e501.
Fu, Y; Gregory, DG; Sippel, KC, et al. The ophthalmologist's role in the management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis. Ocul Surf 2010; 8: 193-203.
Lin, A; Patel, N; Yoo, D, et al. Management of ocular conditions in the burn unit: thermal and chemical burns and Stevens-Johnson syndrome/toxic epidermal necrolysis. J Burn Care Res 2011; 32: 547-560.
Gueudry, J; Roujeau, JC; Binaghi, M, et al. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009; 145: 157-162.
Lebargy, F; Wolkenstein, P; Gisselbrecht, M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997; 23: 1237-1244.
Hague, JS; Goulding, JM; Long, TM, et al. Respiratory involvement in toxic epidermal necrolysis portends a poor prognosis that may not be reflected in SCORTEN. Br J Dermatol 2007; 157: 1294-1296.
de Prost, N; Mekontso-Dessap, A; Valeyrie-Allanore, L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med 2014; 42: 118-128.
Clayton, NA; Kennedy, PJ. Management of dysphagia in toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS). Dysphagia 2007; 22: 187-192.
Kedward, AL; McKenna, K. A fatal case of toxic epidermal necrolysis with extensive intestinal involvement. Clin Exp Dermatol 2009; 34: e484.
Sugimoto, Y; Mizutani, H; Sato, T, et al. Toxic epidermal necrolysis with severe gastrointestinal mucosal cell death: a patient who excreted long tubes of dead intestinal epithelium. J Dermatol 1998; 25: 533-538.
Sakai, N; Yoshizawa, Y; Amano, A, et al. Toxic epidermal necrolysis complicated by multiple intestinal ulcers. Int J Dermatol 2008; 47: 180-182.
Dylewski, ML; Prelack, K; Keaney, T, et al. Asymptomatic hyperamylasemia and hyperlipasemia in pediatric patients with toxic epidermal necrolysis. J Burn Care Res 2010; 31: 292-296.
Blum, L; Chosidow, O; Rostoker, G, et al. Renal involvement in toxic epidermal necrolysis. J Am Acad Dermatol 1996; 34: 1088-1090.
Hung, CC; Liu, WC; Kuo, MC, et al. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol 2009; 29: 633-638.
Meneux, E; Wolkenstein, P; Haddad, B, et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol 1998; 91: 283-287.
Niemeijer, IC; van Praag, MC; van Gemund, N. Relevance and consequences of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in gynecology. Arch Gynecol Obstet 2009; 280: 851-854.
Pacheco, H; Araujo, T; Kerdel, F. Toxic epidermal necrolysis in a pregnant, HIV-infected woman. Int J Dermatol 2002; 41: 600-601.
Rodriguez, G; Trent, JT; Mirzabeigi, M, et al. Toxic epidermal necrolysis in a mother and fetus. J Am Acad Dermatol 2006; 55: S96-98.
Struck, MF; Illert, T; Liss, Y, et al. Toxic epidermal necrolysis in pregnancy: case report and review of the literature. J Burn Care Res 2010; 31: 816-821.
Huang, LY; Lin, CM; Chiou, CC, et al. Rhabdomyolysis as a potential complication of carbamazepine-induced toxic epidermal necrolysis. Clin Biochem 2012; 45: 1531-1532.
Goens, J; Song, M; Fondu, P, et al. Haematological disturbances and immune mechanisms in toxic epidermal necrolysis. Br J Dermatol 1986; 114: 255-259.
Samanci, N; Balci, N; Alpsoy, E. Heterotopic ossification related to toxic epidermal necrolysis in a patient with Behcet's disease. J Dermatol 2005; 32: 469-473.
Kamada, N; Kinoshita, K; Togawa, Y, et al. Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti-Ro/SS-A and a review of the published work. J Dermatol 2006; 33: 616-622.
Sheridan, RL; Schulz, JT; Ryan, CM, et al. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics 2002; 109: 74-78.
Magina, S; Lisboa, C; Leal, V, et al. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology 2003; 207: 33-36.
Haber, J; Hopman, W; Gomez, M, et al. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil 2005; 26: 33-41.
Oplatek, A; Brown, K; Sen, S, et al. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 2006; 27: 26-33.
Arvidson, J; Kildal, M; Linde, T, et al. Toxic epidermal necrolysis and hemolytic uremic syndrome after allogeneic stem-cell transplantation. Pediatr Transplant 2007; 11: 689-693.
Gaultier, F; Rochefort, J; Landru, MM, et al. Severe and unrecognized dental abnormalities after drug-induced epidermal necrolysis. Arch Dermatol 2009; 145: 1332-1333.
Quinn, AM; Brown, K; Bonish, BK, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol 2005; 141: 683-687.
Paquet, P; Paquet, F; Al Saleh, W, et al. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol 2000; 22: 413-417.
Paquet, P; Delvenne, P; Piérard, GE. Drug interactions with normal and TEN epidermal keratinocytes. Curr Drug Saf 2012; 7: 352-356.
Faye, O; Wechsler, J; Roujeau, JC. Cell-mediated immunologic mechanism and severity of TEN. Arch Dermatol 2005; 141: 775-776.
Hermanns-Lê, T; Paquet, P; Piérard-Franchimont, C, et al. Regulatory function of factor-XIIIa-positive dendrocytes in incipient toxic epidermal necrolysis and graft-versus-host reaction. A hypothesis. Dermatology 1999; 198: 184-186.
Paquet, P; Quatresooz, P; Piérard, GE. Factor-XIIIa-positive dendrocytes in drug-induced toxic epidermal necrolysis (Lyell's syndrome): paradoxical activation in skin and rarefaction in lymph nodes. Dermatology 2003; 206: 374-378.
Verneuil, L; Ratajczak, P; Allabert, C, et al. Endothelial cell apoptosis in severe drug-induced bullous eruptions. Br J Dermatol 2009; 161: 1371-1375.
Williams, GP; Mudhar, HS; Leyland, M. Early pathological features of the cornea in toxic epidermal necrolysis. Br J Ophthalmol 2007; 91: 1129-1132.
Puangsricharern, V; Tseng, SC. Cytologic evidence of corneal diseases with limbal stem cell deficiency. Ophthalmology 1995; 102: 1476-1485.
de Sica-Chapman, A; Williams, G; Soni, N, et al. Granulocyte colonystimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN management protocol. Br J Dermatol 2010; 162: 860-865.
Paquet, P; Meuwis, MA; Mazzucchelli, G, et al. Proteomic kinetic analysis of blister fluid and serum in a patient with drug-induced toxic epidermal necrolysis. A comparison with skin immunohistochemistry. Curr Drug Saf 2012; 7: 339-351.
Engelhardt, SL; Schurr, MJ; Helgerson, RB. Toxic epidermal necrolysis:an analysis of referral patterns and steroid usage. J Burn Care Rehabil 1997; 18: 520-524.
Bachot, N; Roujeau, JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003; 4: 561-572.
Auquier-Dunant, A; Mockenhaupt, M; Naldi, L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138: 1019-1024.
Lam, NS; Yang, YH; Wang, LC, et al. Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children. J Microbiol Immunol Infect 2004; 37: 366-370.
Quaglino, P; Caproni, M; Osella-Abate, S, et al. Serum interleukin-13 levels are increased in patients with Stevens-Johnson syndrome/ toxic epidermal necrolysis but not in those with erythema multiforme. Br J Dermatol 2008; 158: 184-186.
Macedo, FI; Faris, J; Lum, LG, et al. Extensive Toxic Epidermal Necrolysis Versus Acute Graft Versus Host Disease After Allogenic Hematopoietic Stem-Cell Transplantation: Challenges in Diagnosis and Management. J Burn Care Res 2014; 35: e431-435.
Takeda, H; Mitsuhashi, Y; Kondo, S, et al. Toxic epidermal necrolysis possibly linked to hyperacute graft-versus-host disease after allogeneic bone marrow transplantation. J Dermatol 1997; 24: 635-641.
Stone, N; Sheerin, S; Burge, S. Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma. Clin Exp Dermatol 1999; 24: 260-262.
Piérard, GE; Hermanns-Lê, T; Paquet, P, et al. Toxic Epidermal Necrolysis and Graft-versus-Host Reaction: Revisiting a Puzzling Similarity. ISRN Dermatol 2013; 2013: 651590.
Whitaker-Menezes, D; Jones, SC; Friedman, TM, et al. An epithelial target site in experimental graft-versus-host disease and cytokinemediated cytotoxicity is defined by cytokeratin 15 expression. Biol Blood Marrow Transplant 2003; 9: 559-570.
Zhan, Q; Signoretti, S; Whitaker-Menezes, D, et al. Cytokeratin15-positive basal epithelial cells targeted in graft-versus-host disease express a constitutive antiapoptotic phenotype. J Invest Dermatol 2007; 127: 106-115.
Hermanns-Lê, T; Paquet, P; Nikkels, AF, et al. Prolonged imiquimod treatment and graft-versus-host reaction: histological mimicry in the skin infiltration pattern of the monocyte-macrophage-dendrocyte lineage. Dermatology 2003; 206: 361-365.
Reed, KM; Sober, AJ. Methotrexate-induced necrolysis. J Am Acad Dermatol 1983; 8: 677-679.
Tummino, C; Barlesi, F; Tchouhadjian, C, et al. Severe cutaneous toxicity after pemetrexed as second line treatment for a refractory non small cell lung cancer. Rev Mal Respir 2007; 24: 635-638.
Sawada, Y; Kawakami, C; Nakamura, M, et al. Toxic epidermal necrosis-like dermatosis induced by the first course of methotrexate. Eur J Dermatol 2009; 19: 397-398.
Primka, EJ, 3rd; Camisa, C. Methotrexate-induced toxic epidermal necrolysis in a patient with psoriasis. J Am Acad Dermatol 1997; 36: 815-818.
Yang, CH; Yang, LJ; Jaing, TH, et al. Toxic epidermal necrolysis following combination of methotrexate and trimethoprimsulfamethoxazole. Int J Dermatol 2000; 39: 621-623.
Cakesen, H; Oner, AF. Toxic epidermal necrolysis in a girl with leukemia receiving methotrexate. Indian Pediatr 2001; 38: 426.
Werchniak, AE; Chaffee, S; Dinulos, JG. Methotrexate-induced bullous acral erythema in a child. J Am Acad Dermatol 2005; 52: S93-95.
Tezer, H; Kuskonmaz, B; Kara, A, et al. Intravenous immunoglobulin in the treatment of severe methotrexate-induced acral erythema. J Pediatr Hematol Oncol 2008; 30: 391-393.
Dickgreber, NJ; Sorensen, JB; Paz-Ares, LG, et al. Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res 2010; 16: 2872-2880.
Piérard-Franchimont, C; Quatresooz, P; Reginster, MA, et al. Revisiting cutaneous adverse reactions to pemetrexed. Oncol Lett 2001; 2: 769-772.
Sabatiello, M; Willemaers, V; Lesuisse, M, et al. Pemetrexed-induced pityriasis lichenoides-like dermatitis. J Eur Acad Dermatol Venereol 2012; 26: 127-129.
Bosch-Barrera, J; Gaztanaga, M; Ceballos, J, et al. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer. Onkologie 2009; 32: 580-584.
Rousseau, AF; Bargues, L; Le Bever, H, et al. Effect of gammahydroxybutyrate on keratinocytes proliferation: a preliminary prospective controlled study in severe burn patients. International Journal of Critical, Illness and Injury Science 2014, Epub Apr 9;
Paquet, P; Piérard, GE. Differential pathomechanisms of epidermal necrolytic blistering diseases. Int J Mol Med 2002; 10: 695-699.
Britschgi, M; Steiner, UC; Schmid, S, et al. T-cell involvement in druginduced acute generalized exanthematous pustulosis. J Clin Invest 2001; 107: 1433-1441.
Schmid, S; Kuechler, PC; Britschgi, M, et al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol 2002; 161: 2079-2086.
Cho, YT; Lin, JW; Chen, YC, et al. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol 2014; 70: 539-548.
Sullivan, JR; Shear, NH. The drug hypersensitivity syndrome: what is the pathogenesis? Arch Dermatol 2001; 137: 357-364.
Barbaud, A; Waton, J; Herbeth, B, et al. Comparison of cytokine gene polymorphism in drug-induced maculopapular eruption, urticaria and drug reaction with eosinophilia and systemic symptoms (DRESS). J Eur Acad Dermatol Venereol 2014; 28: 491-499.
Mandelcorn, R; Shear, NH. Lupus-associated toxic epidermal necrolysis:a novel manifestation of lupus? J Am Acad Dermatol 2003; 48: 525-529.
Baker, MG; Cresce, ND; Ameri, M, et al. Systemic lupus erythematosus presenting as stevens-johnson syndrome/toxic epidermal necrolysis. J Clin Rheumatol 2014; 20: 167-171.
Su, SC; Chung, WH. Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions. Toxins (Basel) 2014; 6: 194-210.
Nayak, S; Acharjya, B. Adverse cutaneous drug reaction. Indian J Dermatol 2008; 53: 2-8.
Yuan, J; Guo, S; Hall, D, et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 2011; 25: 1271-1280.
Sharma, AM; Uetrecht, J. Bioactivation of drugs in the skin: relationship to cutaneous adverse drug reactions. Drug Metab Rev 2014; 46: 1-18.
Mockenhaupt, M; Kelly, JP; Kaufman, D, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol 2003; 30: 2234-2240.
La Grenade, L; Lee, L; Weaver, J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf 2005; 28: 917-924.
Mockenhaupt, M; Messenheimer, J; Tennis, P, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134-1138.
Halevy, S; Ghislain, PD; Mockenhaupt, M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32.
Joao, EC; Calvet, GA; Menezes, JA, et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol 2006; 194: 199-202.
Reddy, RB; Shekar, PC; Chandra, KL, et al. Oral lesions associated with Nevirapine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A report of 10 cases. J Oral Maxillofac Pathol 2013; 17: 431-435.
Mockenhaupt, M; Viboud, C; Dunant, A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128: 35-44.
Ball, R; Ball, LK; Wise, RP, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J 2001; 20: 219-223.
Hilgendorf, I; Casper, J; Sviland, L, et al. Toxic epidermal necrolysis after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 245-246.
Jongen-Lavrencic, M; Schneeberger, PM; van der Hoeven, JG. Ciprofloxacin-induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus. Infection 2003; 31: 428-429.
Horne, NS; Narayan, AR; Young, RM, et al. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev 2006; 5: 160-164.
Aguiar, D; Pazo, R; Duran, I, et al. Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neurooncol 2004; 66: 345-350.
Gravante, G; Delogu, D; Esposito, G, et al. Toxic epidermal necrolysis in oncologic patients. Am J Clin Dermatol 2006; 7: 397-398.
Marque, M; Girard, C; Bessis, D, et al. Acute onset Hodgkin's disease following Lyell's syndrome. Ann Dermatol Venereol 2007; 134: 767-770.
Saiag, P; Caumes, E; Chosidow, O, et al. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992; 26: 567-574.
Rzany, B; Mockenhaupt, M; Stocker, U, et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol 1993; 129: 1059.
Correia, O; Delgado, L; Santos, C, et al. HIV-1 in blister fluid of a patient with toxic epidermal necrolysis and AIDS. Lancet 1994; 344: 1432-1433.
Acheampong, EA; Parveen, Z; Muthoga, LW, et al. Molecular interactions of human immunodeficiency virus type 1 with primary human oral keratinocytes. J Virol 2005; 79: 8440-8453.
Borgiani, P; Di Fusco, D; Erba, F, et al. HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique. Eur J Clin Pharmacol 2014; 70: 275-278.
Rotunda, A; Hirsch, RJ; Scheinfeld, N, et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 2003; 83: 1-9.
Yeung, CK; Ma, SY; Hon, C, et al. Aetiology in sixteen cases of toxic epidermal necrolysis and Stevens-Johnson syndrome admitted within eight months in a teaching hospital. Acta Derm Venereol 2003; 83: 179-182.
Cristallo, AF; Schroeder, J; Citterio, A, et al. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet 2011; 38: 303-309.
Bharadwaj, M; Illing, P; Theodossis, A, et al. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol 2012; 52: 401-431.
Niihara, H; Kakamu, T; Fujita, Y, et al. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol 2012; 39: 594-601.
Pavlos, R; Mallal, S; Ostrov, D, et al. Fever, Rash, and Systemic Symptoms: Understanding the Role of Virus and HLA in Severe Cutaneous Drug Allergy. J Allergy Clin Immunol Pract 2014; 2: 21-33.
Borroni, RG. Pharmacogenetic markers of severe cutaneous adverse drug reactions. G Ital Dermatol Venereol 2014; 149: 219-226.
Chung, WH; Hung, SI. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. J Dermatol Sci 2012; 66: 190-196.
Roychowdhury, S; Vyas, PM; Reilly, TP, et al. Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes. J Pharmacol Exp Ther 2005; 314: 43-52.
Pichler, WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002; 2: 301-305.
Gerber, BO; Pichler, WJ. Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions. AAPS J 2006; 8: E160-165.
Yang, CW; Hung, SI; Juo, CG, et al. HLA-B*1502-bound peptides:implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2007; 120: 870-877.
Chung, WH; Hung, SI; Chen, YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007; 7: 317-323.
Roujeau, JC; Huynh, TN; Bracq, C, et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987; 123: 1171-1173.
Hung, SI; Chung, WH; Jee, SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297-306.
Hung, SI; Chung, WH; Liou, LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102: 4134-4139.
Ueta, M; Sotozono, C; Tokunaga, K, et al. Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol 2007; 143: 367-368.
Lonjou, C; Thomas, L; Borot, N, et al. A marker for Stevens-Johnson syndrome ...: ethnicity matters. Pharmacogenomics J 2006; 6: 265-268.
Pirmohamed, M; Arbuckle, JB; Bowman, CE, et al. Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2007; 8: 1661-1691.
Lonjou, C; Borot, N; Sekula, P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99-107.
Ueta, M; Tokunaga, K; Sotozono, C, et al. HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese. Mol Vis 2008; 14: 550-555.
Dainichi, T; Uchi, H; Moroi, Y, et al. Stevens-Johnson syndrome, druginduced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology 2007; 215: 86-88.
Ueta, M; Sotozono, C; Inatomi, T, et al. Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. Br J Ophthalmol 2007; 91: 962-965.
Le Cleach, L; Delaire, S; Boumsell, L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000; 119: 225-230.
Yawalkar, N; Egli, F; Hari, Y, et al. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000; 30: 847-855.
Pichler, WJ. T cells in drug allergy. Curr Allergy Asthma Rep 2002; 2: 9-15.
Nassif, A; Bensussan, A; Boumsell, L, et al. Toxic epidermal necrolysis:effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114: 1209-1215.
Godfrey, DI; MacDonald, HR; Kronenberg, M, et al. NKT cells: what's in a name? Nat Rev Immunol 2004; 4: 231-237.
Teraki, Y; Kawabe, M; Izaki, S. Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol 2013; 131: 907-909.
Chung, WH; Hung, SI; Yang, JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14: 1343-1350.
Nagasawa, M; Isoda, T; Itoh, S, et al. Analysis of serum granulysin in patients with hematopoietic stem-cell transplantation: its usefulness as a marker of graft-versus-host reaction. Am J Hematol 2006; 81: 340-348.
Nassif, A; Bensussan, A; Dorothee, G, et al. Drug specific cytotoxic Tcells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002; 118: 728-733.
Trapani, JA; Smyth, MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002; 2: 735-747.
Voskoboinik, I; Thia, MC; Fletcher, J, et al. Calcium-dependent plasma membrane binding and cell lysis by perforin are mediated through its C2 domain: A critical role for aspartate residues 429, 435, 483, and 485 but not 491. J Biol Chem 2005; 280: 8426-8434.
Law, RH; Lukoyanova, N; Voskoboinik, I, et al. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature 2010; 468: 447-451.
Lord, SJ; Rajotte, RV; Korbutt, GS, et al. Granzyme B: a natural born killer. Immunol Rev 2003; 193: 31-38.
Bots, M; Medema, JP. Granzymes at a glance. J Cell Sci 2006; 119: 5011-5014.
Bird, CH; Sun, J; Ung, K, et al. Cationic sites on granzyme B contribute to cytotoxicity by promoting its uptake into target cells. Mol Cell Biol 2005; 25: 7854-7867.
Veugelers, K; Motyka, B; Goping, IS, et al. Granule-mediated killing by granzyme B and perforin requires a mannose 6-phosphate receptor and is augmented by cell surface heparan sulfate. Mol Biol Cell 2006; 17: 623-633.
Keefe, D; Shi, L; Feske, S, et al. Perforin triggers a plasma membranerepair response that facilitates CTL induction of apoptosis. Immunity 2005; 23: 249-262.
Heibein, JA; Goping, IS; Barry, M, et al. Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. J Exp Med 2000; 192: 1391-1402.
Sutton, VR; Wowk, ME; Cancilla, M, et al. Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. Immunity 2003; 18: 319-329.
Goping, IS; Sawchuk, T; Rieger, A, et al. Cytotoxic T lymphocytes overcome Bcl-2 inhibition: target cells contribute to their own demise. Blood 2008; 111: 2142-2151.
Paquet, P; De Groote, D; Piérard, GE. Functionally active macrophagederived myeloperoxidase in the skin of drug-induced toxic epidermal necrolysis. Dermatology 2010; 220: 201-207.
Tohyama, M; Watanabe, H; Murakami, S, et al. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2012; 166: 322-330.
Moral, A; Palou, J; Lafuente, A, et al. Immunohistochemical study of alpha, mu and pi class glutathione S transferase expression in malignant melanoma. MMM Group. Multidisciplinary Malignant Melanoma Group. Br J Dermatol 1997; 136: 345-350.
Paquet, P; Piérard, GE. Glutathione-S-transferase pi expression in toxic epidermal necrolysis: a marker of putative oxidative stress in keratinocytes. Skin Pharmacol Physiol 2007; 20: 66-70.
Hayes, JD; Pulford, DJ. The glutathione S-transferase supergene family:regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445-600.
Sarafian, TA; Bredesen, DE. Is apoptosis mediated by reactive oxygen species? Free Radic Res 1994; 21: 1-8.
Lange, RW; Hayden, PJ; Chignell, CF, et al. Anthralin stimulates keratinocyte-derived proinflammatory cytokines via generation of reactive oxygen species. Inflamm Res 1998; 47: 174-181.
Paquet, P; Ribbens, C; Piérard, GE. Epidermal interleukin-8 and its receptor CXCR2 in drug-induced toxic epidermal necrolysis. Clin Exp Dermatol 2007; 32: 728-732.
Herzenberg, LA; De Rosa, SC; Dubs, JG, et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci U S A 1997; 94: 1967-1972.
Korndorfer, IP; Brueckner, F; Skerra, A. The crystal structure of the human (S100A8/S100A9)2 heterotetramer, calprotectin, illustrates how conformational changes of interacting alpha-helices can determine specific association of two EF-hand proteins. J Mol Biol 2007; 370: 887-898.
Korkiamaki, T; Yla-Outinen, H; Koivunen, J, et al. An intact actincontaining cytoskeleton is required for capacitative calcium entry, but not for ATP-induced calcium-mediated cell signaling in cultured human keratinocytes. Med Sci Monit 2003; 9: BR199-207.
Ross, K; Parker, G; Whitaker, M, et al. Inhibition of calciumindependent phospholipase A impairs agonist-induced calcium entry in keratinocytes. Br J Dermatol 2008; 158: 31-37.
Trump, BF; Berezesky, IK. The role of altered [Ca2+]i regulation in apoptosis, oncosis, and necrosis. Biochim Biophys Acta 1996; 1313: 173-178.
Stahlhut, M; Bertelsen, M; Hoyer-Hansen, M, et al. Ingenol mebutate:induced cell death patterns in normal and cancer epithelial cells. J Drugs Dermatol 2012; 11: 1181-1192.
Randhawa, SR; Chahine, BG; Lowery-Nordberg, M, et al. Underexpression and overexpression of Fas and Fas ligand: a doubleedged sword. Ann Allergy Asthma Immunol 2010; 104: 286-292.
Abe, R; Shimizu, T; Shibaki, A, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003; 162: 1515-1520.
Viard-Leveugle, I; Gaide, O; Jankovic, D, et al. TNF-alpha and IFNgamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol 2013; 133: 489-498.
Murata, J; Abe, R; Shimizu, H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol 2008; 122: 992-1000.
Fu, M; Gao, Y; Pan, Y, et al. Recovered patients with Stevens-Johson syndrome and toxic epidermal necrolysis maintain long-lived IFNgamma and sFasL memory response. PLoS One 2012; 7: e45516.
Viard-Leveugle, I; Bullani, RR; Meda, P, et al. Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. J Biol Chem 2003; 278: 16183-16188.
Xiao, S; Jodo, S; Sung, SS, et al. A novel signaling mechanism for soluble CD95 ligand. Synergy with anti-CD95 monoclonal antibodies for apoptosis and NF-kappaB nuclear translocation. J Biol Chem 2002; 277: 50907-50913.
Wilson, NS; Dixit, V; Ashkenazi, A. Death receptor signal transducers:nodes of coordination in immune signaling networks. Nat Immunol 2009; 10: 348-355.
Knox, PG; Milner, AE; Green, NK, et al. Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. J Immunol 2003; 170: 677-685.
Garcia-Doval, I; Florez, A; De La Torre, C, et al. Transient verrucous hyperplasia after toxic epidermal necrolysis. Br J Dermatol 2003; 149: 1082-1083.
Singh, R; Chen, C; Phelps, RG, et al. Stem cells in the skin and their role in oncogenesis. J Eur Acad Dermatol Venereol 2014; 28: 542-549.
Abbas, O; Mahalingam, M. Epidermal stem cells: practical perspectives and potential uses. Br J Dermatol 2009; 161: 228-236.
Schreder, A; Pierard, GE; Paquet, P, et al. Facing towards epidermal stem cells (Review). Int J Mol Med 2010; 26: 171-174.
Jullien, D; Prevot, G; Wolkenstein, P, et al. Eruptive nevus in the course of Lyell syndrome. Ann Dermatol Venereol 1995; 122: 540-542.
Paquet, P; Jacob, E; Quatresooz, P, et al. Delayed reepithelialization and scarring deregulation following drug-induced toxic epidermal necrolysis. Burns 2007; 33: 100-104.
Lehloenya, RJ; Esmail, F; Christians, SJ, et al. Toxic epidermal necrolysis with failure of re-epithelialization. Could umbilical cord mesenchymal stem cell transplantation have a role? J Eur Acad Dermatol Venereol 2013; 27: 923-925.
Ito, K; Takigawa, M. Immune privilege and alopecia areata. Expert Rev Dermatol 2010; 5: 141-148.
Purba, TS; Haslam, IS; Poblet, E, et al. Human epithelial hair follicle stem cells and their progeny: current state of knowledge, the widening gap in translational research and future challenges. Bioessays 2014; 36: 513-525.
Ruckert, R; Lindner, G; Bulfone-Paus, S, et al. High-dose proinflammatory cytokines induce apoptosis of hair bulb keratinocytes in vivo. Br J Dermatol 2000; 143: 1036-1039.
Arnold, R; Seifert, M; Asadullah, K, et al. Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction:modulation by cytokines. J Immunol 1999; 162: 7140-7147.
Seitz, CS; Freiberg, RA; Hinata, K, et al. NF-kappaB determines localization and features of cell death in epidermis. J Clin Invest 2000; 105: 253-260.
Liu, ZG. Molecular mechanism of TNF signaling and beyond. Cell Res 2005; 15: 24-27.
Norman, MU; Lister, KJ; Yang, YH, et al. TNF regulates leukocyteendothelial cell interactions and microvascular dysfunction during immune complex-mediated inflammation. Br J Pharmacol 2005; 144: 265-274.
Kelly, M; Hwang, JM; Kubes, P. Modulating leukocyte recruitment in inflammation. J Allergy Clin Immunol 2007; 120: 3-10.
Caproni, M; Torchia, D; Schincaglia, E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006; 155: 722-728.
Schroder, K; Hertzog, PJ; Ravasi, T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75: 163-189.
Nassif, A; Moslehi, H; Le Gouvello, S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004; 123: 850-855.
Paul, C; Wolkenstein, P; Adle, H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996; 134: 710-714.
Paquet, P; Piérard, GE. Toxic epidermal necrolysis: revisiting the tentative link between early apoptosis and late necrosis (review). Int J Mol Med 2007; 19: 3-10.
Li, J; Yuan, J. Caspases in apoptosis and beyond. Oncogene 2008; 27: 6194-6206.
Correia, O; Delgado, L; Barbosa, IL, et al. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 2002; 47: 58-62.
Lerner, LH; Qureshi, AA; Reddy, BV, et al. Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome. J Invest Dermatol 2000; 114: 196-199.
Marzano, AV; Frezzolini, A; Caproni, M, et al. Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunopathol Pharmacol 2007; 20: 557-566.
Williams, GP; Tomlins, PJ; Denniston, AK, et al. Elevation of conjunctival epithelial CD45INTCD11b(+)CD16(+)CD14(-) neutrophils in ocular Stevens-Johnson syndrome and toxic epidermal necrolysis. Invest Ophthalmol Vis Sci 2013; 54: 4578-4585.
Tapia, B; Padial, A; Sanchez-Sabate, E, et al. Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions. J Allergy Clin Immunol 2004; 114: 335-340.
Mayorga, C; Torres, MJ; Corzo, JL, et al. Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin. Ann Allergy Asthma Immunol 2003; 91: 86-91.
Segura Huerta, AA; Tordera, P; Cercos, AC, et al. Toxic epidermal necrolysis associated with interleukin-2. Ann Pharmacother 2002; 36: 1171-1174.
Inachi, S; Mizutani, H; Shimizu, M. Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Contribution of perforin-positive cell infiltration. Arch Dermatol 1997; 133: 845-849.
Mingari, MC; Ponte, M; Bertone, S, et al. HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen-or alloantigen-activated CD8+ T cells. Proc Natl Acad Sci U S A 1998; 95: 1172-1177.
Caproni, M; Torchia, D; Schincaglia, E, et al. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 2006; 154: 319-324.
Ettorre, A; Andreassi, M; Anselmi, C, et al. Involvement of oxidative stress in apoptosis induced by a mixture of isothiazolinones in normal human keratinocytes. J Invest Dermatol 2003; 121: 328-336.
Armeni, T; Battino, M; Stronati, A, et al. Total antioxidant capacity and nuclear DNA damage in keratinocytes after exposure to H2O2. Biol Chem 2001; 382: 1697-1705.
Glasser, DL; Burroughs, SH. Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. Pharmacotherapy 2003; 23: 551-553.
Huang, LY; Liao, WC; Chiou, CC, et al. Fatal toxic epidermal necrolysis induced by carbamazepine treatment in a patient who previously had carbamazepine-induced Stevens-Johnson syndrome. J Formos Med Assoc 2007; 106: 1032-1037.
Pasricha, JS; Khaitan, BK; Shantharaman, R, et al. Toxic epidermal necrolysis. Int J Dermatol 1996; 35: 523-527.
de Araujo, E; Dessirier, V; Lapree, G, et al. Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol 2011; 20: 107-112.
Piérard, GE; Uhoda, E. Skin photophysics and colors. Rev Med Liege 2005; 60 Suppl 1: 48-52.
Devillers, C; Piérard-Franchimont, C; Schreder, A, et al. High resolution skin colorimetry, strain mapping and mechanobiology. Int J Cosmet Sci 2010; 32: 241-245.
Wilkins, AJ; Nimmo-Smith, I; Jansons, JE. Colorimeter for the intuitive manipulation of hue and saturation and its role in the study of perceptual distortion. Ophthalmic Physiol Opt 1992; 12: 381-385.
Petit, L; Fogouang, L; Uhoda, I, et al. Regional variability in mottled subclinical melanoderma in the elderly. Exp Gerontol 2003; 38: 327-331.
Xhauflaire-Uhoda, E; Piérard-Franchimont, C; Piérard, GE, et al. Weathering of the hairless scalp: a study using skin capacitance imaging and ultraviolet light-enhanced visualization. Clin Exp Dermatol 2010; 35: 83-85.
Hermanns-Lê, T; Piérard-Franchimont, C; Piérard, GE. Scrutinizing skinfield melanin patterns in young Caucasian women. Expert Opin Med Diagn 2013; 7: 455-462.
Lévêque, JL; Xhauflaire-Uhoda, E; Piérard, GE. Skin capacitance imaging, a new technique for investigating the skin surface. Eur J Dermatol 2006; 16: 500-506.
Xhauflaire-Uhoda, E; Piérard, GE; Quatresooz, P. The skin landscape following nonoptical capacitance imaging. Am J Clin Dermatol 2010; 11: 89-94.
Delvenne, M; Piérard-Franchimont, C; Seidel, L, et al. The weatherbeaten dorsal hand clinical rating, shadow casting optical profilometry, and skin capacitance mapping. Biomed Res Int 2013; 2013: 913646.
Piérard, GE. In vivo confocal microscopy: a new paradigm in dermatology. Dermatology 1993; 186: 4-5.
Corcuff, P; Gonnord, G; Piérard, GE, et al. In vivo confocal microscopy of human skin: a new design for cosmetology and dermatology. Scanning 1996; 18: 351-355.
Moscarella, E; Argenziano, G; Lallas, A, et al. Confocal microscopy: a new era in understanding the pathophysiologic background of inflammatory skin diseases. Exp Dermatol 2014; 23: 320-321.
Vera, LS; Gueudry, J; Delcampe, A, et al. In vivo confocal microscopic evaluation of corneal changes in chronic Stevens-Johnson syndrome and toxic epidermal necrolysis. Cornea 2009; 28: 401-407.
Chen, P; Lin, JJ; Lu, CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011; 364: 1126-1133.
Wu, K; Reynolds, NJ. Pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: a critical appraisal. Br J Dermatol 2012; 166: 7-11; discussion 11-14.
Su, SC; Chung, WH. Update on pathobiology in Stevens-Johnson syndrome and toxic epidermal necrolysis. Dermatol Sin 2013; 31: 175-180.
Toh, DS; Tan, LL; Aw, DC, et al. Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study. Pharmacogenomics J 2014; 14: 316-321.
Azukizawa, H; Sano, S; Kosaka, H, et al. Prevention of toxic epidermal necrolysis by regulatory T cells. Eur J Immunol 2005; 35: 1722-1730.
Eliaszewicz, M; Flahault, A; Roujeau, JC, et al. Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. J Am Acad Dermatol 2002; 47: 40-46.
Abo, T. Extrathymic pathways of T-cell differentiation and immunomodulation. Int Immunopharmacol 2001; 1: 1261-1273.
Paquet, P; Jacob, E; Damas, P, et al. Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell's syndrome) after putative beta-lactam crossreactivity:Case report and scrutiny of antibiotic imputability. Crit Care Med 2002; 30: 2580-2583.
Dorafshar, AH; Dickie, SR; Cohn, AB, et al. Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach. Plast Reconstr Surg 2008; 122: 154-160.
Bastuji-Garin, S; Fouchard, N; Bertocchi, M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-153.
Trent, JT; Kirsner, RS; Romanelli, P, et al. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004; 140: 890-892.
Guégan, S; Bastuji-Garin, S; Poszepczynska-Guigne, E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126: 272-276.
Imahara, SD; Holmes, JHt; Heimbach, DM, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res 2006; 27: 270-275.
Cartotto, R; Mayich, M; Nickerson, D, et al. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res 2008; 29: 141-146.
Vaishampayan, SS; Das, AL; Verma, R. SCORTEN: does it need modification? Indian J Dermatol Venereol Leprol 2008; 74: 35-37.
Sekula, P; Liss, Y; Davidovici, B, et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res 2011; 32: 237-245.
Sassolas, B; Haddad, C; Mockenhaupt, M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88: 60-68.
Paquet, P; Jennes, S; Rousseau, AF, et al. Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-ofconcept study. Burns 2014; 40: 1707-1712.
Namdar, T; von Wild, T; Siemers, F, et al. Does hypernatremia impact mortality in Toxic Epidermal Necrolysis? Ger Med Sci 2010; 8: Doc30.
Trent, JT; Kirsner, RS; Romanelli, P, et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 2003; 139: 39-43.
Knight, L; Muloiwa, R; Dlamini, S, et al. Factors Associated with Increased Mortality in a Predominantly HIV-Infected Population with Stevens Johnson Syndrome and Toxic Epidermal Necrolysis. PLoS One 2014; 9: e93543.
Hettiaratchy, S; Moloney, D; Clarke, J. Patients with acute skin loss: are they best managed on a burns unit? Ann R Coll Surg Engl 2001; 83: 26-29.
Palmieri, TL; Greenhalgh, DG; Saffle, JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002; 23: 87-96.
Gerdts, B; Vloemans, AF; Kreis, RW. Toxic epidermal necrolysis: 15 years' experience in a Dutch burns centre. J Eur Acad Dermatol Venereol 2007; 21: 781-788.
Firoz, BF; Henning, JS; Zarzabal, LA, et al. Toxic epidermal necrolysis:five years of treatment experience from a burn unit. J Am Acad Dermatol 2012; 67: 630-635.
Jennes, S; Pierard, GE; Paquet, P. Deciphering supportive treatment strategies for toxic epidermal necrolysis. Curr Drug Saf 2012; 7: 361-366.
Garcia-Doval, I; LeCleach, L; Bocquet, H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323-327.
Kano, Y; Hirahara, K; Mitsuyama, Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007; 62: 1439-1444.
Tang, YH; Mockenhaupt, M; Henry, A, et al. Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis. Clin Exp Allergy 2012; 42: 248-254.
Porebski, G; Pecaric-Petkovic, T; Groux-Keller, M, et al. In vitro drug causality assessment in Stevens-Johnson syndrome -alternatives for lymphocyte transformation test. Clin Exp Allergy 2013; 43: 1027-1037.
Windle, EM. Immune modulating nutrition support for a patient with severe toxic epidermal necrolysis. J Hum Nutr Diet 2005; 18: 311-314.
Coss-Bu, JA; Jefferson, LS; Levy, ML, et al. Nutrition requirements in patients with toxic epidermal necrolysis. Nutr Clin Pract 1997; 12: 81-84.
Mayes, T; Gottschlich, M; Khoury, J, et al. Energy requirements of pediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Nutr Clin Pract 2008; 23: 547-550.
van den Berghe, G; Wouters, P; Weekers, F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-1367.
Tseng, SC. Acute management of Stevens-Johnson syndrome and toxic epidermal necrolysis to minimize ocular sequelae. Am J Ophthalmol 2009; 147: 949-951.
Gregory, DG. The ophthalmologic management of acute Stevens-Johnson syndrome. Ocul Surf 2008; 6: 87-95.
Tougeron-Brousseau, B; Delcampe, A; Gueudry, J, et al. Vision-related function after scleral lens fitting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol 2009; 148: 852-859 e852.
McGee, T; Munster, A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 1998; 102: 1018-1022.
Timsit, JF; Mion, G; Rouyer, N, et al. Bronchopulmonary distress associated with toxic epidermal necrolysis. Intensive Care Med 1992; 18: 42-44.
Dillon, CK; Lloyd, MS; Dzeiwulski, P. Accurate debridement of toxic epidermal necrolysis using Versajet®. Burns 2010; 36: 581-584.
Pianigiani, E; Lerardi, F; Taddeucci, P, et al. Skin allograft in the treatment of toxic epidermal necrolysis (TEN). Dermatol Surg 2002; 28: 1173-1176.
Kobayashi, A; Yoshita, T; Sugiyama, K, et al. Amniotic membrane transplantation in acute phase of toxic epidermal necrolysis with severe corneal involvement. Ophthalmology 2006; 113: 126-132.
Shay, E; Kheirkhah, A; Liang, L, et al. Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis. Surv Ophthalmol 2009; 54: 686-696.
Gregory, DG. Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases. Ophthalmology 2011; 118: 908-914.
Bhattacharya, S; Tripathi, HN; Gupta, V, et al. Collagen sheet dressings for cutaneous lesions of toxic epidermal necrolysis. Indian J Plast Surg 2011; 44: 474-477.
Bannasch, H; Kontny, U; Kruger, M, et al. A semisynthetic bilaminar skin substitute used to treat pediatric full-body toxic epidermal necrolysis: wraparound technique in a 17-month-old girl. Arch Dermatol 2004; 140: 160-162.
Huang, S; Fu, X. Tissue-engineered skin: bottleneck or breakthrough. Int J Burns Trauma 2011; 1: 1-10.
Arevalo, JM; Lorente, JA. Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis. J Burn Care Rehabil 1999; 20: 406-410.
Whitaker, IS; Prowse, S; Potokar, TS. A critical evaluation of the use of Biobrane as a biologic skin substitute: a versatile tool for the plastic and reconstructive surgeon. Ann Plast Surg 2008; 60: 333-337.
Lindford, AJ; Kaartinen, IS; Virolainen, S, et al. Comparison of Suprathel(R) and allograft skin in the treatment of a severe case of toxic epidermal necrolysis. Burns 2011; 37: e67-72.
Pfurtscheller, K; Zobel, G; Roedl, S, et al. Use of Suprathel dressing in a young infant with TEN. Pediatr Dermatol 2008; 25: 541-543.
Asz, J; Asz, D; Moushey, R, et al. Treatment of toxic epidermal necrolysis in a pediatric patient with a nanocrystalline silver dressing. J Pediatr Surg 2006; 41: e9-12.
Huang, SH; Wu, SH; Sun, IF, et al. AQUACEL Ag in the treatment of toxic epidermal necrolysis (TEN). Burns 2008; 34: 63-66.
Smith, SD; Dodds, A; Dixit, S, et al. Role of nanocrystalline silver dressings in the management of toxic epidermal necrolysis (TEN) and TEN/Stevens-Johnson syndrome overlap. Australas J Dermatol 2014
Ng, RW; Cheng, YL. Calcium alginate dressing-related hypercalcemia. J Burn Care Res 2007; 28: 203-204.
Lehrer-Bell, KA; Kirsner, RS; Tallman, PG, et al. Treatment of the cutaneous involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis with silver nitrate-impregnated dressings. Arch Dermatol 1998; 134: 877-879.
Fumal, I; Braham, C; Paquet, P, et al. The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof-of-concept study. Dermatology 2002; 204 Suppl 1: 70-74.
Timsit, JF; Mion, G; Le Gulluche, Y, et al. Severe hypothermia occurring during the course of toxic epidermal necrolysis in patients treated with air-fluidized beds. Arch Dermatol 1991; 127: 739-740.
Boorboor, P; Vogt, PM; Bechara, FG, et al. Toxic epidermal necrolysis:use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients. Burns 2008; 34: 487-492.
Hii, BW; Mahar, PD; Wasiak, J, et al. Hospital management and clinical factors associated with ophthalmic involvement in toxic epidermal necrolysis. Burns 2014; 40: 903-908.
Lopez-Garcia, JS; Rivas, L; Garcia-Lozano, I, et al. Amniotic membrane transplantation in acute toxic epidermal necrolysis: histopathologic changes and ocular surface features after 1-year follow-up. Eur J Ophthalmol 2014; 24: 667-675.
John, T; Foulks, GN; John, ME, et al. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. Ophthalmology 2002; 109: 351-360.
Tandon, A; Cackett, P; Mulvihill, A, et al. Amniotic membrane grafting for conjunctival and lid surface disease in the acute phase of toxic epidermal necrolysis. J AAPOS 2007; 11: 612-613.
Shay, E; Khadem, JJ; Tseng, SC. Efficacy and limitation of sutureless amniotic membrane transplantation for acute toxic epidermal necrolysis. Cornea 2010; 29: 359-361.
Ciralsky, JB; Sippel, KC; Gregory, DG. Current ophthalmologic treatment strategies for acute and chronic Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Opin Ophthalmol 2013; 24: 321-328.
Iyer, G; Srinivasan, B; Agarwal, S, et al. Comprehensive approach to ocular consequences of Stevens Johnson Syndrome -the aftermath of a systemic condition. Graefes Arch Clin Exp Ophthalmol 2014; 252: 457-467.
Shammas, MC; Lai, EC; Sarkar, JS, et al. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthalmol 2010; 149: 203-213 e202.
Sachdev, R; Bansal, S; Sinha, R, et al. Bilateral microbial keratitis in highly active antiretroviral therapy-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a case series. Ocul Immunol Inflamm 2011; 19: 343-345.
Tomlins, PJ; Parulekar, MV; Rauz, S. "Triple-TEN" in the treatment of acute ocular complications from toxic epidermal necrolysis. Cornea 2013; 32: 365-369.
Spies, M; Sanford, AP; Aili Low, JF, et al. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics 2001; 108: 1162-1168.
Paquet, P; Piérard, GE; Quatresooz, P. Novel treatments for druginduced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol 2005; 136: 205-216.
Fromowitz, JS; Ramos-Caro, FA; Flowers, FP. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 2007; 46: 1092-1094.
Marchal, G; Bilski-Pasquier, G; Flandrin, G. On a Severe Type of Pluri-Orificial Ectodermosis. Rapidly Favorable Course Due to Corticotherapy. Bull Mem Soc Med Hop Paris 1964; 115: 717-720.
van der Meer, JB; Schuttelaar, ML; Toth, GG, et al. Successful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to oxazepam. Clin Exp Dermatol 2001; 26: 654-656.
Araki, Y; Sotozono, C; Inatomi, T, et al. Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol 2009; 147: 1004-1011, 1011 e1001.
Viard, I; Wehrli, P; Bullani, R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493.
Ito, K; Hara, H; Okada, T, et al. Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fas-ligand expression. Clin Exp Dermatol 2004; 29: 679-680.
Paquet, P; Kaveri, S; Jacob, E, et al. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. Exp Dermatol 2006; 15: 381-386.
Paquet, P; Jacob, E; Damas, P, et al. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns 2001; 27: 652-655.
Tristani-Firouzi, P; Petersen, MJ; Saffle, JR, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002; 47: 548-552.
Bachot, N; Revuz, J; Roujeau, JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis:a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33-36.
Brown, KM; Silver, GM; Halerz, M, et al. Toxic epidermal necrolysis:does immunoglobulin make a difference? J Burn Care Rehabil 2004; 25: 81-88.
Shortt, R; Gomez, M; Mittman, N, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004; 25: 246-255.
Faye, O; Roujeau, JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs 2005; 65: 2085-2090.
Tan, AW; Thong, BY; Yip, LW, et al. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol 2005; 32: 1-6.
French, LE; Trent, JT; Kerdel, FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol 2006; 6: 543-549.
Mittmann, N; Chan, B; Knowles, S, et al. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol 2006; 7: 359-368.
Stella, M; Clemente, A; Bollero, D, et al. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns 2007; 33: 452-459.
Huang, YC; Li, YC; Chen, TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol 2012; 167: 424-432.
Yip, LW; Thong, BY; Tan, AW, et al. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye (Lond) 2005; 19: 846-853.
Paquet, P; Piérard, GE. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology 1999; 198: 198-202.
Arevalo, JM; Lorente, JA; Gonzalez-Herrada, C, et al. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000; 48: 473-478.
Hashim, N; Bandara, D; Tan, E, et al. Early cyclosporine treatment of incipient toxic epidermal necrolysis induced by concomitant use of lamotrigine and sodium valproate. Acta Derm Venereol 2004; 84: 90-91.
Valeyrie-Allanore, L; Wolkenstein, P; Brochard, L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010; 163: 847-853.
Danby, FW. Ciclosporin use in toxic epidermal necrolysis. Br J Dermatol 2007; 156: 390-391.
Paquet, P; Jacob, E; Damas, P, et al. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res 2005; 297: 266-273.
Fischer, M; Fiedler, E; Marsch, WC, et al. Antitumour necrosis factoralpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002; 146: 707-709.
Al-Shouli, S; Abouchala, N; Bogusz, MJ, et al. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol 2005; 85: 534-535.
Hunger, RE; Hunziker, T; Buettiker, U, et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 2005; 116: 923-924.
Meiss, F; Helmbold, P; Meykadeh, N, et al. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. J Eur Acad Dermatol Venereol 2007; 21: 717-719.
Famularo, G; Di Dona, B; Canzona, F, et al. Etanercept for toxic epidermal necrolysis. Ann Pharmacother 2007; 41: 1083-1084.
Wolkenstein, P; Latarjet, J; Roujeau, JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-1589.
Velez, A; Moreno, JC. Toxic epidermal necrolysis treated with Nacetylcysteine. J Am Acad Dermatol 2002; 46: 469-470.
Redondo, P; de Felipe, I; de la Pena, A, et al. Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine. Br J Dermatol 1997; 136: 645-646.
Yavuz, H; Emiroglu, M. Toxic epidermal necrolysis treated with Nacetylcysteine. Pediatr Int 2014; 56: e52-54.
Sanclemente, G; De la Roche, CA; Escobar, CE, et al. Pentoxyfylline in toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 1999; 38: 878-879.
Frangogiannis, NG; Boridy, I; Mazhar, M, et al. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 1996; 89: 1001-1003.
Ang, CC; Tay, YK. Hematological abnormalities and the use of granulocyte-colony-stimulating factor in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Dermatol 2011; 50: 1570-1578.
Inamo, Y; Okubo, T; Wada, M, et al. Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Three case reports. Int Arch Allergy Immunol 2002; 127: 89-94.
Egan, CA; Grant, WJ; Morris, SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999; 40: 458-461.
Yamada, H; Takamori, K. Status of plasmapheresis for the treatment of toxic epidermal necrolysis in Japan. Ther Apher Dial 2008; 12: 355-359.
Narita, YM; Hirahara, K; Mizukawa, Y, et al. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol 2011; 38: 236-245.
Nomura, T; Abe, R; Fujimoto, K, et al. Plasma exchange; a promising treatment for toxic epidermal necrolysis with AIDS. AIDS 2004; 18: 2446-2448.
Lissia, M; Figus, A; Rubino, C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg 2005; 58: 504-510.
De Vriese, AS; Colardyn, FA; Philippe, JJ, et al. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999; 10: 846-853.
Furubacke, A; Berlin, G; Anderson, C, et al. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? Intensive Care Med 1999; 25: 1307-1310.
Kumar, R; Dohlman, CH; Chodosh, J. Oral acetazolamide after Boston keratoprosthesis in Stevens-Johnson syndrome. BMC Res Notes 2012; 5: 205.
